skip to main content

Our M&A lawyers are among the most experienced and effective in the world. We represent many of the world's largest publicly traded and privately held companies, as well as leading private equity firms, financial advisors and other financial institutions and investors on their most important mergers, acquisitions and takeover transactions.

Foresite Capital Acquires Pardes Biosciences

Paul, Weiss advised MediPacific, Inc., a Foresite Capital Management company, in its acquisition of Pardes Biosciences, Inc. Pardes, a developer of novel oral antiviral therapeutics for life-threatening diseases, including COVID-19, is now a subsidiary of MediPacific.

Under the deal terms, MediPacific acquired Pardes for $2.13 per share in cash, plus a non-tradeable contingent value right associated with any future monetization of Pardes’ COVID-19 antiviral portfolio and related intellectual property.

The Paul, Weiss team was led by corporate partners Austin Pollet, Jeffrey Marell and Luke Jennings, and included corporate partner Lindsey Wiersma and counsel Usman Arain, Laura Schnaidt and Jason Tyler; tax partners Matthew Jordan and Patrick Karsnitz; executive compensation partner Andrea Wahlquist Brown; intellectual property partner Jonathan Ashtor; litigation partner Andrew Gordon and counsel Steven Herzog; and antitrust counsel Marta Kelly.

© 2023 Paul, Weiss, Rifkind, Wharton & Garrison LLP

Privacy Policy